Literature DB >> 17220538

Involvement of cannabinoid CB1 receptors in drug addiction: effects of rimonabant on behavioral responses induced by cocaine.

Małgorzata Filip1, Anna Gołda, Magdalena Zaniewska, Andrew C McCreary, Ewa Nowak, Wacław Kolasiewicz, Edmund Przegaliński.   

Abstract

A lot of evidence indicate that endocannabinoids and cannabinoid CB(1) receptors are implicated in drug addiction. In the present study, we investigated the effect of the cannabinoid CB(1) receptor antagonist/partial agonist rimonabant on the cocaine-maintained reinforcement and relapse to cocaine seeking as well as on the cocaine challenge-induced hyperactivity in sensitized rats and on discriminative stimulus effects of cocaine in rats. We found that endocannabinoids were not involved in maintenance of cocaine reinforcement and its subjective effects since pharmacological blockade of cannabinoid CB(1) receptors altered neither self-administration nor discriminative stimulus effects of cocaine. On the other hand, withdrawal from repeated access or exposure to cocaine and then a reinstatement of cocaine-seeking behavior or a sensitized locomotor response to a single cocaine challenge, respectively, was potently reduced by pretreatment with rimonabant. The latter observations may show that repeated cocaine treatment and the drug withdrawal produce--apart from behavioral effects--also different neural consequences in the endocannabinoid systems in rats.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17220538

Source DB:  PubMed          Journal:  Pharmacol Rep        ISSN: 1734-1140            Impact factor:   3.024


  42 in total

1.  Cannabinoid CB1 receptors mediate the effects of corticotropin-releasing factor on the reinstatement of cocaine seeking and expression of cocaine-induced behavioural sensitization.

Authors:  D A Kupferschmidt; P G Klas; S Erb
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

Review 2.  The endocannabinoid system in brain reward processes.

Authors:  M Solinas; S R Goldberg; D Piomelli
Journal:  Br J Pharmacol       Date:  2008-04-14       Impact factor: 8.739

Review 3.  Endocannabinoid-mediated synaptic plasticity and addiction-related behavior.

Authors:  Nimish Sidhpura; Loren H Parsons
Journal:  Neuropharmacology       Date:  2011-06-12       Impact factor: 5.250

Review 4.  Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors.

Authors:  Antonia Serrano; Loren H Parsons
Journal:  Pharmacol Ther       Date:  2011-07-18       Impact factor: 12.310

5.  The cannabinoid CB2 receptor is necessary for nicotine-conditioned place preference, but not other behavioral effects of nicotine in mice.

Authors:  Bogna M Ignatowska-Jankowska; Pretal P Muldoon; Aron H Lichtman; M Imad Damaj
Journal:  Psychopharmacology (Berl)       Date:  2013-05-08       Impact factor: 4.530

Review 6.  Role of cues and contexts on drug-seeking behaviour.

Authors:  Christina J Perry; Isabel Zbukvic; Jee Hyun Kim; Andrew J Lawrence
Journal:  Br J Pharmacol       Date:  2014-07-02       Impact factor: 8.739

7.  Endocannabinoid signaling in neurotoxicity and neuroprotection.

Authors:  C Pope; R Mechoulam; L Parsons
Journal:  Neurotoxicology       Date:  2009-12-05       Impact factor: 4.294

8.  Chronic unpredictable stress enhances cocaine-conditioned place preference in type 1 cannabinoid receptor knockout mice.

Authors:  Laurence L Miller; Sara J Ward; Linda A Dykstra
Journal:  Behav Pharmacol       Date:  2008-09       Impact factor: 2.293

Review 9.  Inhibition of FAAH and activation of PPAR: new approaches to the treatment of cognitive dysfunction and drug addiction.

Authors:  Leigh V Panlilio; Zuzana Justinova; Steven R Goldberg
Journal:  Pharmacol Ther       Date:  2013-01-16       Impact factor: 12.310

10.  Attenuation of basal and cocaine-enhanced locomotion and nucleus accumbens dopamine in cannabinoid CB1-receptor-knockout mice.

Authors:  Xia Li; Alexander F Hoffman; Xiao-Qing Peng; Carl R Lupica; Eliot L Gardner; Zheng-Xiong Xi
Journal:  Psychopharmacology (Berl)       Date:  2008-12-20       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.